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Short title: Perceptions of hospital quality incentive for antibiotic use  17 
Structured Synopsis  18 
Background: In 2016/2017, a financially-linked antibiotic prescribing quality improvement 19 
initiative (AMR-CQUIN) was introduced across acute hospitals in England. This aimed for 20 
>1% reductions in Defined Daily Doses / 1000 admissions of total antibiotics, 21 
piperacillin/tazobactam and carbapenems compared with 2013/2014 and improved review 22 
of empiric antibiotic prescriptions. 23 
Objectives: To assess perceptions of staff leading antimicrobial stewardship activity about 24 
the AMR-CQUIN, the investments made by hospitals to achieve it and how these related to 25 
achieving reductions in antibiotic use.  26 
Methods: We invited antimicrobial stewardship leads at acute hospitals across England to 27 
complete a web-based survey. Antibiotic prescribing data were downloaded from the Public 28 
Health England Antimicrobial Resistance local Indicators resource. 29 
Results: Responses were received from 116/155 (75%) acute hospitals. Due to yearly 30 
increases in antibiotic use, most trusts needed to make >5% reductions in antibiotic 31 
consumption to achieve the AMR-CQUIN goal of 1% reduction. Additional funding was made 32 
available at 23/113 (20%) trusts, and in 18 (78%), this was <10% of the AMR-CQUIN value. 33 
Nationally, the annual trend for increased antibiotic use reversed in 2016/2017. In 34 
2014/2015 year-on-year changes were +3.7% (IQR[-0.8, +8.4], +9.4%[+0.2, +19.5] and 35 
+5.8%[-6.2, +18.2] for total antibiotics, piperacillin/tazobactam and carbapenems 36 
respectively and +0.1%[-5.4, +4.0], -4.8%[-16.9, +3.2] and -8.0%[-20.2, +4.0] in 2016/2017. 37 
Hospitals where staff believed they could reduce antibiotic use were more likely to do so 38 
(p<0.001). 39 
Conclusions: Introducing the AMR-CQUIN was associated with a reduction in antibiotic use. 40 
For individual hospitals, achieving the AMR-CQUIN was associated with favourable 41 
perceptions of staff and not availability of funding. 42 
43 
Introduction  44 
Antimicrobial consumption is linked to antimicrobial resistance (AMR) both in populations 45 
and in individual people.1,2 As much as 50% of human antibiotic use may be unnecessary3 46 
and reducing this overuse is a major priority in healthcare systems across the world.4,5  47 
In the United Kingdom NHS, hospitals are responsible for a minority of total antibiotic use 48 
but they are almost exclusively where the most broad-spectrum antibiotics such as 49 
piperacillin/tazobactam and the carbapenems are prescribed.6 Avoiding antibiotic overuse 50 
in hospitals is challenging because patients with clinically significant bacterial infections 51 
require prompt administration of effective antibiotics, almost always before definitive 52 
diagnostic information is available. Initiatives to prevent avoidable deaths from infection 53 
encourage rapid administration of reliably active antibiotics to patients who meet broad 54 
clinical criteria for sepsis; however, many of these antibiotics are subsequently deemed 55 
unnecessary.7 Despite a succession of initiatives in the NHS, such as increased funding for 56 
antimicrobial stewardship (AMS) (2003),8 a requirement in law for hospital trusts to ensure 57 
appropriate antimicrobial use (2008),9 and development of an Antimicrobial Toolkit for 58 
English hospitals called ‘Start Smart Then Focus’ (SSTF) (2011),10 antibiotic use in National 59 
Health Service (NHS) hospitals has increased, year-on-year up until 2014.11  60 
In 2015, NHS England required Clinical Commissioning Groups to submit their local baseline 61 
prescribing data to enable validation of prescribing patterns and antibiotic use.12 The 62 
following year saw the introduction of the first Commissioning for Quality and Innovation 63 
(CQUIN) for antibiotic prescribing (AMR-CQUIN).13 CQUINs are the main mechanism by 64 
which the NHS encourages hospitals to focus on the quality of care delivered by making a 65 
proportion of income conditional on achieving specific quality measures. The AMR-CQUIN 66 
was worth 0.25% of acute trust income (approximately £650,000 for an average size 67 
hospital based on the number of inpatient beds). Given the emphasis in SSTF on review and 68 
revision of antibiotic prescriptions as a key activity to control antibiotic use in hospitals, the 69 
four AMR-CQUIN components included empiric review of >90% of antibiotic prescriptions 70 
within 72 hours along with reductions in antibiotic use (defined daily doses per 1000 71 
admissions) of ≥1% compared with baseline (2013/2014 data) for 1) total antibiotics 2) 72 
piperacillin/tazobactam and 3) carbapenems.13 Hospital trusts were required by NHS 73 
England to submit antibiotic consumption data to PHE for the preceding years, 2014/2015 74 
and 2016/2017, and received an additional payment for the submission of this data. All data 75 
submitted were published on the ‘Fingertips’ Antimicrobial Resistance (AMR) Local Indicator 76 
data portal as part of the English Surveillance Programme for Antimicrobial Utilisation and 77 
Resistance (ESPAUR).14 Fingertips provides access to a wide range of local public health data 78 
presented as thematic profiles. It acts as an important national repository of data on 79 
antimicrobial use, AMR, infection prevention control data and hospital acquired infection 80 
data.15 Following the introduction of the AMR-CQUIN, AMS leads at individual hospitals 81 
anecdotally reported varying success in securing financial investment to support achieving 82 
these quality improvements and expressed anxiety about achieving the antibiotic reductions 83 
needed to meet the AMR-CQUIN. The aim of this study was to establish how the AMR-84 
CQUIN was perceived by the staff responsible for achieving it at individual hospitals, 85 
evaluate to what extent trusts made funding available to achieve it and finally explore 86 
whether these factors had an impact on hospitals achieving reductions in antibiotic 87 
consumption.  88 
Methods 89 
A web-based survey (www.surveymonkey.com) was developed, piloted with three hospital 90 
AMS leads and refined. The full survey is available in the supplementary materials. An email 91 
invitation to participate was sent to AMS leads at acute hospital NHS trusts on Dec 8th, 2016. 92 
The names and contact details used were compiled by one of the investigators (D-AO) as 93 
part of network development within ESPAUR. The people contacted had agreed to 94 
represent their organisations in communications with ESPAUR particularly related to the 95 
AMR-CQUIN activities. The survey was voluntary, two reminders were sent to recipients 96 
who didn’t respond initially. No incentives were offered and there was no advertising of the 97 
survey. The survey asked for information about: AMS team structures and activity, the 98 
reductions needed to achieve each AMR-CQUIN component, whether funding was in place 99 
to achieve this and perceptions about the AMR-CQUIN. The survey closed to respondents on 100 
5th March 2017. Where more than one survey was submitted from a hospital, the survey 101 
containing the greater number of completed fields was included. Any discordant answers 102 
were checked with the submitting hospital before removing the duplicate survey. In 103 
reporting the survey we have used the CHERRIES checklist for reporting results of Internet E-104 
Surveys. 16 A completed checklist is available in the supplementary materials.  105 
Hospital trust level data on antibiotic consumption were downloaded from ESPAUR using 106 
data submitted by acute hospital NHS trusts since 2013 using a standardised spreadsheet 107 
provided to organisations. Data extracted from the survey was analysed using SPSS Version 108 
24 (IBM®, UK) and GraphPad Prism™. Categorical variables were compared using Fisher’s 109 
exact tests and continuous variables using the Wilcoxon signed-rank test. According to 110 
current NHS Health Research Authority (HRA) guidance (available at www.hra.org.uk) ethical 111 
approval was not required for this study as this was a service evaluation of NHS staff. All 112 
antibiotic consumption data included was openly available.  113 
Results 114 
AMS at hospital trusts included in the survey 115 
Responses were received from a total of 116/155 (75%) acute hospital trusts in England. The 116 
majority of surveys were completed by the lead antimicrobial pharmacist (64/116 [55%]), 117 
followed by another pharmacist (28/116 [24%]), the hospital lead-antimicrobial clinician 118 
(22/116 [19%]) and in two cases the infection prevention control nurse (2/116 [2%]).  119 
108/116 (94%) respondents reported their hospital had an AMS committee which met 120 
quarterly or more often. AMS committees always included a microbiologist and 121 
antimicrobial pharmacist. Additional committee members varied with representation from 122 
acute medicine (78/116, 67%), surgery (64/116, 55%), paediatrics (49/116, 42%), intensive 123 
care (42/116, 36%), infection prevention director (47/116, 41%) and clinical commissioners / 124 
General Practice representatives (55/116, 47%). Microbiology / Infection trainee doctors 125 
were on the AMS committee in only 27/116 (23%) trusts. 126 
NICE guidance on AMS processes and systems had been considered at the AMS committee 127 
in 108/116 (93%) trusts and 94/116 (81%) respondents reported completing the NICE AMS 128 
baseline audit tool which helps identify areas to improve compliance with the guidance. A 129 
total of 72/116 (62%) trusts had formally reviewed SSTF, a further 27/116 (23%) trusts had 130 
informally reviewed SSTF and 64/116 (55.3%) had an action plan for its implementation. 131 
Most respondents (105/116, 91%) reported that their trust had accessed the AMR Local 132 
Indicators data on ‘Fingertips’ and this data has been shared with their AMS committee 133 
(82/116, 71%), immediate colleagues (79/116, 68%), Trust Boards (37/116, 32%) or 134 
commissioners (33/116, 28%). Only six respondents (5%) indicated data had been shared 135 
with front-line clinical staff. 136 
Achieving the CQUIN measures 137 
Although the AMR-CQUIN aimed to achieve reductions of ≥1% compared to baseline 138 
(2013/14), in many trusts antibiotic consumption had continued to rise between 2013/2014 139 
and the introduction of the AMR-CQUIN in April 2016. Consequently, most trusts needed to 140 
achieve much larger reductions than ≥1% in in 2016/2017 compared with 2015/2016 (Table 141 
1).  142 
Changes in antibiotic use after introduction of the AMR CQUIN  143 
Data gathered by ESPAUR from 130 acute hospital NHS trusts reporting annual data from 144 
2013 onwards showed that increases in antibiotic use began to reverse in the 2015/2016 145 
financial year, when trusts were first obliged to report usage data to ESPAUR (Figure 1). In 146 
that year, small but statistically significant year-on-year reductions were measured for total 147 
antibiotic use (p<0.0001), piperacillin/tazobactam use (p<0.0001) and carbapenem use 148 
(p=0.05). In the AMR-CQUIN year (ending March 2017) there was no evidence that total 149 
antibiotic consumption changed compared to the previous year +0.1% (-5.4, +4.0, p=0.05), 150 
but there were substantial and statistically significant reductions in piperacillin/tazobactam 151 
use of -4.8% (-16.9, +3.2, p<0.0001) and carbapenem use of-8.0% (-20.2, +4.0, p<0.001). 152 
However, there was striking variation between trusts. Changes in antibiotic consumption in 153 
2016/2017 compared to a baseline of 2013/2014 ranged from -43% to +71% for total 154 
antibiotic use, -17% to +72% for piperacillin/tazobactam use and -79% to +44% for 155 
carbapenem use. 156 
Of the surveyed trusts participating in the AMR-CQUIN, 41/111 (37%) achieved the quality 157 
measure for piperacillin/tazobactam, 61/111 (55%) for carbapenems and 48/111 (43%) for 158 
total antibiotic use (Table 2) based on information reported to PHE. The median reduction in 159 
antibiotic consumption compared to the 2013/2014 baseline achieved in those trusts 160 
surveyed was -0.2% (-11.9, +10.1) for total antibiotic use, +2.2% (-18.0, +18.3) for 161 
piperacillin/tazobactam and -7.8% (-29.4, +12.1) for carbapenems. The attitudes of AMS 162 
leaders to the AMR-CQUIN or availability of additional trust funding were not associated 163 
with achieving the CQUIN goals (p>0.3, Table 2). Substantially more trusts achieved the 164 
AMR-CQUIN where the survey respondents were optimistic about meeting the CQUIN 165 
(p<0.0001, Table 2). 166 
Funding towards achieving the CQUIN 167 
Five of the trusts surveyed reported a decision had been taken not to participate in the 168 
AMR-CQUIN. A total of 68/116 (59%) trusts set out to meet the nationally set CQUIN 169 
reductions. Within the remaining trusts, 43/116 had negotiated local variations in some 170 
(18/116, 16%) or all (25/116, 22%) of the components. Funding had been made available to 171 
support achieving the AMR-CQUIN at only 23/113 (20%) participating trusts. Even where 172 
funding was made available in 18/23 (78%) trusts, the funding amount was <10% of the 173 
overall AMR-CQUIN value. 174 
Perceptions and achieving the CQUIN 175 
At the time the survey was conducted, the AMR-CQUIN had been in place for approximately 176 
6 months. Respondents were pessimistic about achieving the targets, and only a minority 177 
felt their trust would achieve the necessary reductions for piperacillin/tazobactam (31/116, 178 
27%), carbapenems (42/116, 36%) and total antibiotic use (34/116, 29%). Exactly half of the 179 
respondents (58/116, 50%) agreed with the statement that the AMR-CQUIN had changed 180 
AMS activity in their trust and 35/116 (30%) felt the AMR-CQUIN would reduce antibiotic 181 
consumption. However, only 22/116 (19%) felt that it would do so safely. Accordingly, 182 
82/116 (71%) respondents were interested in the possibility of participating in research to 183 
evaluate how to safely optimize antibiotic review and revise.   184 
Discussion  185 
Reducing unnecessary antibiotic use among hospitalised patients is challenging because the 186 
need to ensure prompt effective empiric antibiotic treatment for patients with suspected 187 
life-threatening infection, coupled with fear of antibiotic resistance, drives increased use of 188 
the ‘ultra-broad-spectrum’ antibiotics that include piperacillin/tazobactam and 189 
carbapenems that have been linked to AMR. In the UK, NHS ‘Start Smart then Focus’ (SSTF) 190 
attempts to address this challenge by asking prescribers to regularly review and revise 191 
empiric antibiotic prescriptions. Similar approaches are applied in other European Countries 192 
17and in the United States.18 Prescribers find review and revise is challenging.19 Without 193 
robust measures to support it review and revise may not be effective in balancing drivers to 194 
increase use of broad-spectrum antibiotics in hospitalised patients.20 It is encouraging that 195 
this survey has demonstrated not only a high level of awareness of NICE guidance and SSTF 196 
but also that over half the trusts now have an action plan for SSTF (55.3%) compared with 197 
46% in  2014.21  198 
Our findings that most hospitals have multidisciplinary AMS teams, meeting regularly who 199 
had considered the relevant NICE guidance and assessed their activity against it, all illustrate 200 
how well AMS is embedded in NHS hospitals, as it is elsewhere in high-income settings 201 
where regulatory measures are in force. 22 We did not gather detailed data on adequate 202 
staffing or specific action plans which have been highlighted as key gaps strategic needs in 203 
AMS programmes.23 We were focused on the impact of the specific AMR-CQUIN 204 
intervention but our finding that so little new funding was made available even at trusts 205 
which achieved their targets suggests increased staffing was not a key factor.  206 
A starting point for our study was concern that pharmacists and microbiologists responsible 207 
for AMS at individual hospitals doubted both the feasibility and safety of achieving the 208 
reductions required to achieve the CQUIN goals. By surveying the staff responsible for 209 
implementing AMS at acute trusts in England, we have determined that many staff did 210 
indeed have significant concerns about whether the AMR-CQUIN could be safely 211 
implemented. Although we did not explore the basis for concern, it is likely that prescribers 212 
are worried that efforts to reduce unnecessary antibiotic use may increase the risk of under-213 
treatment of patients who need antibiotics. This is unsurprising given how few studies 214 
assessing antimicrobial reduction strategies in hospitalised patients have included 215 
meaningful clinical outcome data.24 216 
Many hospitals were confronted with needing to make much greater reductions in antibiotic 217 
use in 2016/2017 to achieve a >1% reduction in antibiotic use, because of year-on-year 218 
increases in antibiotic use from a baseline (2013/2014) set two years prior to the 219 
introduction of the AMR-CQUIN. Consequently, several trusts either elected not to try and 220 
achieve the goals as set out or, when they did, they were unwilling to allocate even a small 221 
amount of the money they would lose for not achieving them, to improve stewardship 222 
activity. Nevertheless, while neither concern about safety of the AMR-CQUIN nor lack of 223 
financial investment to achieve it appear to have impacted on the AMR-CQUIN being 224 
achieved, hospitals where staff were positive about its success were much more likely to 225 
achieve the reductions in antibiotic use required.  226 
Our finding that only around half the hospitals surveyed achieved the antibiotic reduction 227 
targets is in striking contrast with the fact that ESPAUR data record that  almost all trusts 228 
achieved the CQUIN target of 90% antibiotic prescriptions being reviewed.14 However the 229 
explanation for this is likely to be that review more commonly results in continuing or 230 
changing treatment than discontinuation. ESPAUR data also report that only a small 231 
minority of antibiotic prescriptions are stopped at review and revise (nationally an average 232 
of 7.8% during the last quarter of the financial year 2016-17.14 This in keeping with how 233 
hard prescribers find it to stop antibiotic prescriptions that have already been written.19 234 
Despite this, our data confirm that antimicrobial use in English hospitals started to decline in 235 
2015/2016, the year that commissioners were first required to report antibiotic prescribing 236 
data from acute hospitals. This may be a ‘Hawthorne effect’, explained by an increased 237 
awareness and modification of prescribing habits by trust staff due to an increase in data 238 
collection in the year prior to the introduction of the quality improvement itself. While we 239 
find no overall further reduction in antibiotic use in the year the AMR-CQUIN was 240 
introduced, the marked reductions seen in piperacillin/tazobactam and carbapenem use 241 
suggests a move away from these two ‘ultra-broad-spectrum’ agents to alternatives, 242 
potentially increasing total antibiotic DDD by the use of more than one antibiotic.  243 
Our study has limitations. Although the survey highlighted ongoing concern that the AMR-244 
CQUIN may not be able to safely reduce antibiotic consumption we did not collect detailed 245 
information about the reasons for concerns. The survey was carried out six months after the 246 
AMR-CQUIN had started, which may have influenced respondents’ perceptions about 247 
whether they would achieve the CQUIN. We sought a single response from each hospital 248 
and did not quality control the responses but respondents attested their leadership role in 249 
AMS at their trust and were asked to complete the survey in discussion with colleagues so 250 
we believe responses are likely to be reliable. Finally, we were not able to extract detailed 251 
information about the specific actions taken following introduction of the AMR-CQUIN 252 
which may have allowed individual trusts to achieve reductions, nor whether the total 253 
reductions resulted from shorter treatment durations or fewer patients being treated and 254 
whether overall appropriateness of treatment improved. There is a need for future work to 255 
understand these mechanisms better to support antibiotic optimization more widely.   256 
Despite these limitations, our findings indicate that the AMR-CQUIN approach of setting 257 
goals backed up by robust data gathering and reporting has helped hospitals achieve 258 
reductions in antibiotic overuse. Positive staff attitudes rather than availability of new 259 
funding are likely to have been important at hospitals which achieved the reduction goals. 260 
Further efforts to improve review and revise decision making as a key element of hospital 261 
AMS practice will need both evidence and novel tools to support clinical decision and 262 
reassure staff that patient safety is not compromised when stopping unnecessary 263 
antibiotics.  264 
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Table 1. Reductions in antibiotic use required to achieve the AMR-CQUIN targets. Of those trusts surveyed, data was available for 107/116 351 
trusts for piperacillin/tazobactam and carbapenems and for 108/116 trusts for total antibiotic consumption. 352 
 353 
 354 
  355 
Antibiotic reductions needed  
to achieve AMR-CQUIN (%) 
Piperacillin/tazobactam 
n=107 (%) 
Carbapenems 
n=107 (%) 
Total antibiotic 
n=108 (%) 
<1% 11 (10%) 23 (21%) 17 (16%) 
1-5% 14 (13%) 14 (13%) 24 (22%) 
5-10% 11 (10%) 8 (7%) 19 (18%) 
10-20% 23 (21%) 15 (14%) 21 (19%) 
>20% 25 (23%) 24 (22%) 5 (5%) 
Not known 23 (21%) 23 (21%) 22 (20%) 
Table 2. Impact of funding and attitudes on Trusts achieving the AMR-CQUIN. (a) 3 respondents did not answer this question. (b) 39 356 
respondents were unsure whether the CQUIN would reduce antibiotic consumption and 13 did not answer this question. (c) 19 respondents 357 
were unsure whether the CQUIN had changed AMS and 11 did not answer this question (d) 57 respondents were unsure whether the CQUIN 358 
would safely reduce antibiotic consumption and 11 did not answer this question (e) In total 26, 28 and 29 respondents did not answer this 359 
question for piperacillin/tazobactam, carbapenems and total antibiotics respectively. 360 
 Piperacillin/tazobactam (n=109) Carbapenems (n=109) Total antibiotic (n=108) 
 Achieved 
n=41 (%) 
Not 
Achieved 
n=68 (%) 
p Achieved 
n=61 (%) 
Not Achieved 
n=48 (%) 
p Achieved  
n=48 (%) 
Not 
Achieved 
n=60 (%) 
p 
Funding(a) available (n=23) 10 (24%) 13 (19%)  0.63 16 (26%) 7 (15%) 0.32 11 (23%) 12 (20%) 0.60 
Funding not available 
(n=90) 
30 (73%) 53 (78%) 43 (70%) 40 (83%) 36 (75%) 46 (77%) 
CQUIN will help reduce 
antibiotic consumption (b) 
(n =35) 
16 (39%) 16 (24%) 0.34 18 (30%) 15 (31%) 0.94 14 (29%) 18 (30%) 0.96 
CQUIN will not help reduce 
antibiotic consumption  
(n=29) 
11 (27%) 16 (24%) 15 (25%) 12 (25%) 10 (21%) 17 (28%) 
CQUIN will change AMS (C) 21 (51%) 32 (47%) 0.84 22 (36%) 30 (63%) 0.42 30 (63%) 23 (38%) 0.53 
CQUIN will not change 
AMS(C) 
10 (24%) 17 (25%) 15 (25%) 12 (25%)  12 (25%) 15 (25%) 
CQUIN will safely reduce 
antibiotic consumption (d) 
6 (15%) 14 (21%) 0.87 7 (11%) 13 (27%) 0.87 8 (17%) 12 (20%) 0.99 
CQUIN will not safely reduce 
antibiotic consumption (d) 
11 (27%) 13 (19%) 10 (16%) 14 (29%) 10 (21%) 14 (23%) 
Trust predicted that they 
would achieve CQUIN (e) 
26 (63%) 2 (3%) <0.0001* 40 (66%) 1 (2%) <0.0001* 31 (65%) 1 (2%) <0.0001* 
Trust predicted that they 6 (15%) 53 (78%) 4 (6%) 42 (88%) 5 (10%) 48 (80%) 
would not achieve CQUIN (e)  
 361 
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  363 
Figure 1. Year-on-year changes in antibiotic use at acute hospitals in England. Boxes show medians and quartiles, whiskers 5 and 95 364 
percentiles. P values are Wilcoxon sign rank,  2-tailed. 365 
 366 
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